Aplysin sensitizes cancer cells to TRAIL by suppressing p38 MAPK/survivin pathway

Marine Drugs

Volumn 12, Issue 9, 2014, Pages 5072-5088

  Liu, Jia ^a,b   Ma, Leina ^c   Wu, Ning ^a   Liu, Ge ^a,b   Zheng, Lanhong ^d   Lin, Xiukun ^a,e  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

^d YELLOW SEA FISHERIES RESEARCH INSTITUTE   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Aplysin; p38 MAPK; Survivin; TRAIL

Indexed keywords

APLYSIN; BROMINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SESQUITERPENE DERIVATIVE; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; BROMINATED HYDROCARBON; INHIBITOR OF APOPTOSIS PROTEIN; SESQUITERPENE; TUBULIN; TUBULIN MODULATOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HUMANS; HYDROCARBONS, BROMINATED; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SESQUITERPENES; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUBULIN; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908032208     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12095072     Document Type: Article

References (24)

1. Pan, G.; O'Rourke, K.; Chinnaiyan, A.M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276, 111-113.
2. Yerbes, R.; Palacios, C.; Lopez-Rivas, A. The therapeutic potential of TRAIL receptor signaling in cancer cells. Clin. Transl. Oncol. 2011, 13, 839-847.
3. Dimberg, L.Y.; Anderson, C.K.; Camidge, R.; Behbakht, K.; Thorburn, A.; Ford, H.L. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2012, 32, 1341-1350.
4. Maksimovic-Ivanic, D.; Stosic-Grujicic, S.; Nicoletti, F.; Mijatovic, S. Resistance to TRAIL and how to surmount it. Immunol. Res. 2012, 52, 157-168.
5. Kawasaki, H.; Altieri, D.C.; Lu, C.D.; Toyoda, M.; Tenjo, T.; Tanigawa, N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58, 5071-5074.
6. Griffith, T.S.; Fialkov, J.M.; Scott, D.L.; Azuhata, T.; Williams, R.D.; Wall, N.R.; Altieri, D.C.; Sandler, A.D. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 2002, 62, 3093-3099.
7. Shigeno, M.; Nakao, K.; Ichikawa, T.; Suzuki, K.; Kawakami, A.; Abiru, S.; Miyazoe, S.; Nakagawa, Y.; Ishikawa, H.; Hamasaki, K.; et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 2003, 22, 1653-1662.
8. Gimenez-Bonafe, P.; Tortosa, A.; Perez-Tomas, R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targets 2009, 9, 320-340.
9. Sakai, T.; Eskander, R.N.; Guo, Y.; Kim, K.J.; Mefford, J.; Hopkins, J.; Bhatia, N.N.; Zi, X.; Hoang, B.H. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J. Orthop. Res. 2012, 30, 1045-1050.
10. Jacquemin, G.; Granci, V.; Gallouet, A.S.; Lalaoui, N.; Morle, A.; Iessi, E.; Morizot, A.; Garrido, C.; Guillaudeux, T.; Micheau, O. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 2012, 97, 38-46.
11. Chen, W.; Wang, X.; Zhuang, J.; Zhang, L.; Lin, Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 2007, 28, 2114-2121.
12. Fulda, S.; Debatin, K.M. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signaling. Eur. J. Cancer 2005, 41, 786-798.
13. Pellerito, O.; Calvaruso, G.; Portanova, P.; de Blasio, A.; Santulli, A.; Vento, R.; Tesoriere, G.; Giuliano, M. The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol. Pharmacol. 2010, 77, 854-863.
14. Ge, N.; Liang, H.; Liu, Y.; Ma, A.G.; Han, L. Protective effect of Aplysin on hepatic injury in ethanol-treated rats. Food Chem. Toxicol. 2013, 62, 361-372.
15. Hasegawa, H.; Yamada, Y.; Komiyama, K.; Hayashi, M.; Ishibashi, M.; Sunazuka, T.; Izuhara, T.; Sugahara, K.; Tsuruda, K.; Masuda, M.; et al. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production. Blood 2007, 110, 1664-1674.
16. Lee, J.; Hwangbo, C.; Lee, J.J.; Seo, J.; Lee, J.H. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol. Re. 2010, 23, 229-237.
17. Minakawa, T.; Toume, K.; Ahmed, F.; Sadhu, S.K.; Ohtsuki, T.; Arai, M.A.; Ishibashi, M. Constituents of Pongamia pinnata isolated in a screening for activity to overcome tumor necrosis factor-related apoptosis-inducing ligand-resistance. Chem. Pharm. Bull. 2010, 58, 1549-1551.
18. Depraetere, V.; Golstein, P. Fas and other cell death signaling pathways. Semin. Immunol. 1997, 9, 93-107.
19. Lin, Y.; Liu, X.; Yue, P.; Benbrook, D.M.; Berlin, K.D.; Khuri, F.R.; Sun, S.Y. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol. Cancer Ther. 2008, 7, 3556-3565.
20. Waiwut, P.; Inujima, A.; Inoue, H.; Saiki, I.; Sakurai, H. Bufotalin sensitizes death receptor-induced apoptosis via Bid- and STAT1-dependent pathways. Int. J. Oncol. 2012, 40, 203-208.
21. Ryu, B.J.; Hwang, M.K.; Park, M.; Lee, K.; Kim, S.H. Thiourea compound AW00178 sensitizes human H1299 lung carcinoma cells to TRAIL-mediated apoptosis. Bioorg. Med. Chem. Lett. 2013, 22, 3862-3865.
22. Hsu, Y.F.; Sheu, J.R.; Lin, C.H.; Yang, D.S.; Hsiao, G.; Ou, G.; Chiu, P.T.; Huang, Y.H.; Kuo, W.H.; Hsu, M.J. Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim. Biophys. Acta 2012, 1820, 104-115.
23. Sun, J.; Shi, D.; Ma, M.; Li, S.; Wang, S.; Han, L.; Yang, Y.; Fan, X.; Shi, J.; He, L. Sesquiterpenes from the red alga Laurencia tristicha. J. Nat. Prod. 2005, 68, 915-919.
24. Weng, D.; Song, X.; Xing, H.; Ma, X.; Xia, X.; Weng, Y.; Zhou, J.; Xu, G.; Meng, L.; Zhu, T.; et al. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett. 2009, 273, 257-265.